Browse the world's most comprehensive database of hedge fund investor letters, sorted by recent quarter. Access primary source research from leading institutional managers.
Browse the world's most comprehensive archive of hedge fund manager letters. Access primary source research from leading institutional managers, sorted by reporting period.
Aristotle International underperformed in Q2, swapping Novartis for Roche in pharmaceuticals while Cameco led on nuclear energy tailwinds. Consulting headwinds hurt Accenture despite strong AI bookings. The fund maintains its quality-focused, fundamentals-driven approach, avoiding macro predictions while seeking companies with competitive advantages and compelling catalysts across international markets.
Full Quick Take
Aristotle International underperformed in Q2, swapping Novartis for Roche in pharmaceuticals while Cameco led on nuclear energy tailwinds. Consulting headwinds hurt Accenture despite strong AI bookings. The fund maintains its quality-focused, fundamentals-driven approach, avoiding macro predictions while seeking companies with competitive advantages and compelling catalysts across international markets.
